Pyrosequencing AB Provides Fast Answers in Clinical Research and Forensics

--Company introduces a new solution for Sequence Analysis --



Apr 11, 2001, 01:00 ET from Pyrosequencing AB

    UPPSALA, Sweden, April 11 /PRNewswire/ --Pyrosequencing AB (SSE: PYRO A),
 today announced the availability of a new solution for DNA sequence analysis
 that provides fast answers in clinical research and forensic investigations.
 The analysis of specific DNA sequences is used increasingly in areas such as
 clinical microbiology to improve the diagnosis and treatment of infectious
 diseases and in forensics for the identification of a DNA sample in an
 investigation. In these areas, fast results are often a critical factor.
 Samples can now be processed in parallel within less than one hour using new
 Sequence Analysis Software and Reagent Kits together with the Company's
 well-established PSQ(TM) 96 System for DNA sequencing.
     "We see a great potential for Pyrosequencing to become a routine tool in
 clinical microbiology," says Professor Lars Engstrand of the Department of
 Medical Sciences, Clinical Bacteriology, Uppsala University. "With
 conventional techniques it can take days to identify or characterize bacteria
 or viruses. The simplicity and reliability of Pyrosequencing's sequence
 analysis products can shorten this to a few hours."
     "This new application follows on rapidly from the success of our first
 products for SNP analysis which, in less than one year, have become
 established and recognized worldwide for their accuracy, reliability and ease
 of use," said Erik Wallden, President and CEO of Pyrosequencing AB. "It is
 also further evidence of the broad utility of our Pyrosequencing(TM)
 technology for all areas of applied genetic analysis. We believe that the
 unique attributes of our technology platform are equally well suited for
 developing solutions in molecular diagnostics and we continue to explore
 applications for this market."
     Marie Allen, Assistant Professor at the Department of Genetics and
 Pathology/Medical Genetics, Rudbeck Laboratory, Uppsala, Sweden works with
 this new technology in her role as a forensic investigator: "After only three
 months testing, we already use Pyrosequencing to get the answers we need for
 our ongoing casework. We get much faster results compared to our existing
 techniques and they are more easily interpreted."
     "The need for fast analysis of gene-specific sequences is of increasing
 importance in both clinical and criminal investigations," adds Marten Winge,
 VP World Wide Marketing and Support. "This new solution will provide a unique
 opportunity for clinical and forensic laboratories to use the latest genetic
 analysis technology for faster analysis and increased confidence in the
 results."
     Pyrosequencing continues to receive orders for its PSQ(TM) 96 System,
 which has rapidly penetrated the European, U.S., and Japanese markets.  The
 accuracy and reliability of applications based on Pyrosequencing(TM)
 technology has already been proven in the field of SNP analysis - single
 nucleotide polymorphisms: the most common variation found in genetic material.
 The PSQ 96 System can perform rapid, accurate and reproducible SNP analysis
 and Sequence Analysis - the analysis of DNA sequences used for identification
 and characterization- by simply selecting the appropriate software and
 reagents.
 
     About Pyrosequencing AB
     Pyrosequencing AB develops, manufactures and sells complete solutions for
 applied genetic analysis based on its proprietary Pyrosequencing(TM)
 technology, a simple-to-use DNA sequencing technique. In the post-genome era,
 Pyrosequencing's technology has established the Company as one of the leading
 suppliers of solutions for accurate, consistent DNA analysis in research
 institutions and pharmaceutical, genomics and agbiotech companies.
 For the analysis of single nucleotide polymorphisms (SNPs) the PSQ(TM) 96
 System with SNP Software and SNP Reagent Kits is used by customers such as
 AstraZeneca, GlaxoSmithKline, the Harvard Center for Cancer Prevention, the
 National Institutes of Health (NIH), DuPont Agriculture, and the National
 Cancer Centre (NCC) in Japan. The Company's Sequence Analysis Software and
 Reagent Kits together with the PSQ 96 System are used for the analysis of
 specific DNA sequences for applications such as bacterial and viral typing
 where speed and ease of use are essential.
     The Company is headquartered in Uppsala, Sweden with North American
 operations located in Westborough, Massachusetts. Pyrosequencing AB also has
 sales offices and distribution partners in Europe, Japan and the Middle East.
 Pyrosequencing AB is listed on the OM Stockholm Exchange. The Company's web
 address is www.pyrosequencing.com.
 
     Certain statements in this press release are forward-looking. These may be
 identified by the use of forward-looking words or phrases such as "believe,"
 "expect," "intend," "anticipate," "should," "planned," "estimated," and
 "potential," among others. These forward-looking statements are based on
 Pyrosequencing's current expectations. The Private Securities Litigation
 Reform Act of 1995 provides a "safe harbor" for such forward-looking
 statements. In order to comply with the terms of the safe harbor,
 Pyrosequencing notes that a variety of factors could cause actual results and
 experience to differ materially from the anticipated results or other
 expectations expressed in such forward-looking statements. Such uncertainties
 and risks include, but are not limited to, risks associated with management of
 growth and international operations (including the effects of currency
 fluctuations), variability of operating results, the commercial development of
 the DNA sequencing and genomics market, nucleic acid-based molecular
 diagnostics market, and genetic vaccination and gene therapy markets,
 competition, rapid or unexpected changes in technologies, fluctuations in
 demand for Pyrosequencing's products (including seasonal fluctuations),
 difficulties in successfully adapting the Company's products to integrated
 solutions and producing such products, and the Company's ability to identify
 and develop new products and to differentiate its products from competitors
 
      FOR FURTHER INFORMATION CONTACT:
      President and CEO
      Erik Wallden
      Pyrosequencing AB
      E-MAIL: erik.wallden@pyrosequencing.com
      Phone: +46 18 565902 or 070 326 98 70
 
      Investor/Public Relations
      Theresa McNeely
      Pyrosequencing AB
      E-MAIL: tmcneely@pyrosequencing-inc.com
      Phone: + 1-508-389-1794
 
      Central Marketing
      Helena Nilshans
      Pyrosequencing AB
      E-MAIL: helena.nilshans@pyrosequencing.com
      Phone: +46 18 565928
 
 

SOURCE Pyrosequencing AB
    UPPSALA, Sweden, April 11 /PRNewswire/ --Pyrosequencing AB (SSE: PYRO A),
 today announced the availability of a new solution for DNA sequence analysis
 that provides fast answers in clinical research and forensic investigations.
 The analysis of specific DNA sequences is used increasingly in areas such as
 clinical microbiology to improve the diagnosis and treatment of infectious
 diseases and in forensics for the identification of a DNA sample in an
 investigation. In these areas, fast results are often a critical factor.
 Samples can now be processed in parallel within less than one hour using new
 Sequence Analysis Software and Reagent Kits together with the Company's
 well-established PSQ(TM) 96 System for DNA sequencing.
     "We see a great potential for Pyrosequencing to become a routine tool in
 clinical microbiology," says Professor Lars Engstrand of the Department of
 Medical Sciences, Clinical Bacteriology, Uppsala University. "With
 conventional techniques it can take days to identify or characterize bacteria
 or viruses. The simplicity and reliability of Pyrosequencing's sequence
 analysis products can shorten this to a few hours."
     "This new application follows on rapidly from the success of our first
 products for SNP analysis which, in less than one year, have become
 established and recognized worldwide for their accuracy, reliability and ease
 of use," said Erik Wallden, President and CEO of Pyrosequencing AB. "It is
 also further evidence of the broad utility of our Pyrosequencing(TM)
 technology for all areas of applied genetic analysis. We believe that the
 unique attributes of our technology platform are equally well suited for
 developing solutions in molecular diagnostics and we continue to explore
 applications for this market."
     Marie Allen, Assistant Professor at the Department of Genetics and
 Pathology/Medical Genetics, Rudbeck Laboratory, Uppsala, Sweden works with
 this new technology in her role as a forensic investigator: "After only three
 months testing, we already use Pyrosequencing to get the answers we need for
 our ongoing casework. We get much faster results compared to our existing
 techniques and they are more easily interpreted."
     "The need for fast analysis of gene-specific sequences is of increasing
 importance in both clinical and criminal investigations," adds Marten Winge,
 VP World Wide Marketing and Support. "This new solution will provide a unique
 opportunity for clinical and forensic laboratories to use the latest genetic
 analysis technology for faster analysis and increased confidence in the
 results."
     Pyrosequencing continues to receive orders for its PSQ(TM) 96 System,
 which has rapidly penetrated the European, U.S., and Japanese markets.  The
 accuracy and reliability of applications based on Pyrosequencing(TM)
 technology has already been proven in the field of SNP analysis - single
 nucleotide polymorphisms: the most common variation found in genetic material.
 The PSQ 96 System can perform rapid, accurate and reproducible SNP analysis
 and Sequence Analysis - the analysis of DNA sequences used for identification
 and characterization- by simply selecting the appropriate software and
 reagents.
 
     About Pyrosequencing AB
     Pyrosequencing AB develops, manufactures and sells complete solutions for
 applied genetic analysis based on its proprietary Pyrosequencing(TM)
 technology, a simple-to-use DNA sequencing technique. In the post-genome era,
 Pyrosequencing's technology has established the Company as one of the leading
 suppliers of solutions for accurate, consistent DNA analysis in research
 institutions and pharmaceutical, genomics and agbiotech companies.
 For the analysis of single nucleotide polymorphisms (SNPs) the PSQ(TM) 96
 System with SNP Software and SNP Reagent Kits is used by customers such as
 AstraZeneca, GlaxoSmithKline, the Harvard Center for Cancer Prevention, the
 National Institutes of Health (NIH), DuPont Agriculture, and the National
 Cancer Centre (NCC) in Japan. The Company's Sequence Analysis Software and
 Reagent Kits together with the PSQ 96 System are used for the analysis of
 specific DNA sequences for applications such as bacterial and viral typing
 where speed and ease of use are essential.
     The Company is headquartered in Uppsala, Sweden with North American
 operations located in Westborough, Massachusetts. Pyrosequencing AB also has
 sales offices and distribution partners in Europe, Japan and the Middle East.
 Pyrosequencing AB is listed on the OM Stockholm Exchange. The Company's web
 address is www.pyrosequencing.com.
 
     Certain statements in this press release are forward-looking. These may be
 identified by the use of forward-looking words or phrases such as "believe,"
 "expect," "intend," "anticipate," "should," "planned," "estimated," and
 "potential," among others. These forward-looking statements are based on
 Pyrosequencing's current expectations. The Private Securities Litigation
 Reform Act of 1995 provides a "safe harbor" for such forward-looking
 statements. In order to comply with the terms of the safe harbor,
 Pyrosequencing notes that a variety of factors could cause actual results and
 experience to differ materially from the anticipated results or other
 expectations expressed in such forward-looking statements. Such uncertainties
 and risks include, but are not limited to, risks associated with management of
 growth and international operations (including the effects of currency
 fluctuations), variability of operating results, the commercial development of
 the DNA sequencing and genomics market, nucleic acid-based molecular
 diagnostics market, and genetic vaccination and gene therapy markets,
 competition, rapid or unexpected changes in technologies, fluctuations in
 demand for Pyrosequencing's products (including seasonal fluctuations),
 difficulties in successfully adapting the Company's products to integrated
 solutions and producing such products, and the Company's ability to identify
 and develop new products and to differentiate its products from competitors
 
      FOR FURTHER INFORMATION CONTACT:
      President and CEO
      Erik Wallden
      Pyrosequencing AB
      E-MAIL: erik.wallden@pyrosequencing.com
      Phone: +46 18 565902 or 070 326 98 70
 
      Investor/Public Relations
      Theresa McNeely
      Pyrosequencing AB
      E-MAIL: tmcneely@pyrosequencing-inc.com
      Phone: + 1-508-389-1794
 
      Central Marketing
      Helena Nilshans
      Pyrosequencing AB
      E-MAIL: helena.nilshans@pyrosequencing.com
      Phone: +46 18 565928
 
 SOURCE  Pyrosequencing AB